The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review.
The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review.
复制标题
作者：
在过去的35年里，各种系统治疗复发性或难治性脑膜瘤已被调查。本综述汇总了目前文献中关于这些治疗的安全性和有效性的证据，并评估了正在进行的脑膜瘤药物治疗试验。本研究的结果将有助于未来的研究，看看已经研究了哪些治疗方案，哪些靶点是有希望的干预候选者，以及目前正在进行的临床试验是如何设计的。各种药物治疗方案治疗难治性脑膜瘤的安全性和有效性一直是研究的焦点。我们提出了一个全面的审查，以前的努力和正在进行的临床试验的现状。对国家医学图书馆的MEDLINE和ClinicalTrial.gov数据库进行PRISMA合规审查。纳入文献的主要关注结局为放射学缓解、总生存期、无进展生存期、6个月无进展生存期和不良事件。总体而言，34项已完成的试验和27项正在进行的临床试验符合条件。在已完成的研究中，6-100%的患者报告了6个月无进展生存期。血液系统疾病是最常见的不良事件。在确定的正在进行的临床试验中，9项研究是I期临床试验，11项是II期试验，2项是I期和II期试验，1项是II期和III期试验，2项试验没有指定的阶段。目前，对于难治性或复发性脑膜瘤没有有效的化疗。已经开发了几种有前途的靶向药物，目前正在研究中，希望确定新的治疗策略，用于治疗这种病理。
For the last 35 years, various systemic therapies for recurrent or refractory meningiomas have been investigated. The present review aggregated the currently available evidence in the literature regarding the safety and efficacy of these treatments and assessed the ongoing trials of medical therapy for meningiomas. The findings of the present study would assist future research in seeing what therapeutic regimens have been investigated, which targets are promising candidates for interventions, and how the ongoing clinical trials are currently designed. The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov databases of the National Library of Medicine were performed. The primary outcomes of interest for included articles were radiographic response, overall survival, progression-free survival, six-month progression-free survival, and adverse events. Overall, 34 completed trials and 27 ongoing clinical trials were eligible. Six-month progression-free survival was reported in 6–100% of patients in the completed studies. Hematological disorders were the most common adverse events. Of the ongoing clinical trials identified, nine studies are phase I clinical trials, eleven are phase II trials, two are phase I and II trials, one is phase II and III, and two trials do not have a designated phase. Currently, there is no effective chemotherapy for refractory or recurrent meningiomas. Several promising targeted agents have been developed and are currently being investigated in the hope of identifying novel therapeutic strategies for the treatment of this pathology.
登录
查看更多内容
影响因子：
--
作者：
Arasanz H;Gato-Cañas M;Zuazo M;Ibañez-Vea M;Breckpot K;Kochan G;Escors D
通讯作者：
Escors D
影响因子：
--
作者：
Du Z;Abedalthagafi M;Aizer AA;McHenry AR;Sun HH;Bray MA;Viramontes O;Machaidze R;Brastianos PK;Reardon DA;Dunn IF;Freeman GJ;Ligon KL;Carpenter AE;Alexander BM;Agar NY;Rodig SJ;Bradshaw EM;Santagata S
通讯作者：
Santagata S
影响因子：
15.9
作者：
Abedalthagafi, Malak;Bi, Wenya Linda;Santagata, Sandro
通讯作者：
Santagata, Sandro
影响因子：
4.1
作者：
Gupta, Saksham;Bi, Wenya Linda;Dunn, Ian F.
通讯作者：
Dunn, Ian F.
影响因子：
9.9
作者：
Chamberlain, MC;Tsao-Wei, DD;Groshen, S
通讯作者：
Groshen, S